3652 results for «231»
3652 results
Coronary artery access and revascularisation after TAVI
21 Nov 2021 – From PCR London Valves 2021
Find out more about coronary access post-TAVI in this PCR London Valves 2021 session, witness a coronary intervention after self-expanding TAVI or SAVR in low-risk patients, and review two-year outcomes following TAVI or SAVR in patients stratified by need for revascularisation, among others!
Pacemaker implantation after TAVI
21 Nov 2021 – From PCR London Valves 2021
Through this series of videos from PCR London Valves 2021, learn about the early outcomes of using the novel frame alignment technique during TAVI to improve pacemaker rates, see how cusp overlap projection reduces the burden of permanent pacemaker implantation after TAVR, appreciate the clinical utility of...
TAVI in bicuspid aortic valves
21 Nov 2021 – From PCR London Valves 2021
Thanks to this series of videos from PCR London Valves 2021, analyze the results of self-expandable versus balloon-expandable transcatheter valves in bicuspid aortic anatomy, study the outcomes after TAVI in bicuspid aortic valve, and much more!
TAVI procedure planning and optimising patient outcomes
21 Nov 2021 – From PCR London Valves 2021
Watch this series of videos from PCR London Valves 2021 to evaluate whether TAVICT scans can replace invasive coronary angiography pre-TAVI, to appreciate how pre-operative computed tomography evaluation of aortic burden can predict acute kidney injury post-TAVR, and to appraise mortality in TAVI patients converted to...
PCR London Valves 2021 Hotlines / Late-Breaking Trials: GALILEO, JenaValve TAVI, ENVISAGE TAVI AF, VKA in patients with AF after TAVI
21 Nov 2021 – From PCR London Valves 2021
In this session, find out more about the JenaValve TAVI system in patients with aortic regurgitation, get results from the GALILEO trial, review a late-breaking on-treatment major bleeding analysis from the ENVISAGE TAVI AF trial, and explore the safety and efficacy of edoxaban versus VKA in patients with AF...
Outcomes after novel transcatheter and surgical tricuspid valve interventions
21 Nov 2021 – From PCR London Valves 2021
Find out more about TRI-SCORE, a new risk score to predict in-hospital mortality after isolated tricuspid valve surgery, 30-day outcomes for transcatheter tricuspid repair from the TriBAND study, both the CLASP TR early feasibility and TRISCEND studies six-month results, and more in this PCR London Valves...
Transcatheter mitral, aortic and pulmonary valve implantation
21 Nov 2021 – From PCR London Valves 2021
Watch this series of videos from PCR London Valves 2021 to learn about acute heart failure hospitalizations following TAVI in the U.S., share a peripheral hospital's experiences with structural valve service modernization, enjoy percutaneous transseptal mitral valve implantation in Brazil, and more!
Outcomes following transcatheter and percutaneous mitral valve repair
21 Nov 2021 – From PCR London Valves 2021
CLASP study, predictability of post-delivery residual mitral regurgitation, MiCLASP PMCF study, off-pump transapical neochord implantation, pronostic impact of nutritional status, and patients with low, intermediate and high frailty are the focus of this session from PCR LV 2021 devoted to percutaneous and transcatheter mitral valve repair.
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
